Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin for Post COVID-19 Condition (PCC)
2023-504087-42-00Phase 3Withdrawn
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Aug 2023
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-COVID syndrome comparing Plitidepsin (Aplidin) with Placebo (2 arms). Planned start Aug 2023; status: withdrawn.
02
Drugs
plitidepsin
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2023-504087-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504087-42-00.